Welcome to the Investor Relations page of SYNLAB
SYNLAB AG has completed the admission of its shares in the regulated market segment (Prime Standard) of the Frankfurt Stock Exchange. In this section, you can find all relevant documents related to the Initial Public Offering (IPO) of our company.
โWe have delivered a remarkable growth story over the past years. The planned IPO is a consequent next step for us to realise our full potential as a publicly listed company.
Our primary purpose is to serve customers by providing accurate test results with the highest possible medical precision, the best help to diagnose and the shortest possible turnaround time. Diagnostics will continue to gain importance in the provision of healthcare services as medical practitioners and patients focus more on early detection, prevention and management of diseases.
We will continue with the diligent implementation of our growth strategy and leverage our medical, operational and commercial leadership in Europe as well as in selected emerging markets to create value for shareholders.โ
Mathieu Floreani, CEO of SYNLAB Group
IPO related documents
Here you will find all current documents
Pricing Announcement
Here you find the press release and ad hoc announcement on the final offer price for the IPO of SYNLAB.
Release Announcement
Intention to float
Here you find our press release which includes details on our intended listing.
Company Presentation & Factsheet
Here you can download our company presentation and Factsheet to learn more about our business and our vision.
Price Range Announcement
Here you find the press release which includes information on the price range for the planned IPO.
Download
Prospectus for the IPO
Here you can download the prospectus for the
planned IPO.
Prospectus Summary
Your Investor Relations Contact
You have questions or are interested in receiving news
related to the SYNLAB IPO directly to your e-mail?